Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 17Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma, Alveolar Soft Part 1Osteosarcoma 1Neoplasm Metastasis 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Gastrointestinal Stromal Tumors 1Desmoid Tumors 1Carcinoma, Non-Small-Cell Lung 1Bone Neoplasms 1

Interventions

Ibandronic Acid 8Gemcitabine 8Doxorubicin 6Cyclophosphamide 6Zoledronic Acid 5Radiation 4Nivolumab 4Irinotecan 4pembrolizumab 3Vincristine 3Temozolomide 3Magnetic Resonance Spectroscopy 3Ipilimumab 3Docetaxel 3Denosumab 3Cisplatin 33-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 3regorafenib 2pegfilgrastim 2Tranexamic Acid 2Trabectedin 2Surveys and Questionnaires 2Sunitinib 2Standard of Care 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Radiosurgery 2Quality of Life 2Proton Therapy 2Observation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bone Neoplasms × anlotinib × Sarcoma × Clear all
NCT03527888 2019-05-21

Study of Anlotinib in Patients With Primary Malignant Bone Tumors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Unknown
40 enrolled
Sarcoma

Bone Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡